Abstract 5102
Background
Gastric cancer (GC) is one of the leading cause of cancer death in China, which is mainly caused by environmental and genetic risk factors. By far, the nature of the genetic factors related to gastric cancer has not been well-studied. The aim of this study was to assess the frequency of germline mutations in Chinese gastric cancer population.
Methods
Genomic profiling of DNA was performed through next-generation sequencing (NGS) on tissue or liquid biopsy from patients with gastric cancer between January 01, 2017 and May 07, 2019. Patients with germline pathogenic mutations were identified, and their clinical information were collected.
Results
750 gastric cancer patients were ultimately included for analysis. There were 476 (63.5%) male and 274 (36.5%) female patients. The median age was 61 (range, 26-88). A total of 27 (3.6%) pathogenic germline pathogenic mutations were identified in 13 genes from these patients. The mutations fell most frequently in BRCA2 (0.93%), ATM (0.67%), PALB2 (0.4%), CHEK2 (0.27%), and CDH1 (0.27%), which has been previously reported to underlie hereditary diffuse gastric cancer. Of all these mutations, 9 (69.2%) genes lay in the DNA damage repair pathways, including BRCA1, BRCA2, ATM, PALB2, CHEK2, MRE11A, ATR, and two DNA mismatch repair genes, MLH1 and MSH6, the mutation of which usually result in the presence of microsatellite instability (MSI) in tumor tissues.
Conclusions
This is the first study to explore the spectrum of pathogenic germline mutations in Chinese patients with gastric cancer. Our study has provided valuable clues for the assessment of the corresponding genetic susceptibility in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beijing Cancer Hospital.
Funding
Has not received any funding.
Disclosure
Z. Zhao: Full / Part-time employment: 3D Medicines Inc. Y. Zhang: Full / Part-time employment: 3D Medicines Inc. S. Cai: Full / Part-time employment: 3D Medicines Inc. All other authors have declared no conflicts of interest.
Resources from the same session
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract
3425 - Feasibility and impact of prospective DPYD screening in the Irish population
Presenter: Mohammed Zameer
Session: Poster Display session 2
Resources:
Abstract
1972 - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study
Presenter: Dawn Chong
Session: Poster Display session 2
Resources:
Abstract
4103 - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy
Presenter: Erin Stella Sullivan
Session: Poster Display session 2
Resources:
Abstract
4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.
Presenter: Bozena Cybulska-Stopa
Session: Poster Display session 2
Resources:
Abstract
3554 - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)
Presenter: Pia Österlund
Session: Poster Display session 2
Resources:
Abstract
4572 - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey
Presenter: Iga Rawicka
Session: Poster Display session 2
Resources:
Abstract
4783 - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study
Presenter: Jeeyoo Lee
Session: Poster Display session 2
Resources:
Abstract
5106 - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study
Presenter: Christina Siesing
Session: Poster Display session 2
Resources:
Abstract
3364 - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Presenter: Mohamed Oukkal
Session: Poster Display session 2
Resources:
Abstract